# Viviant 20mg Special Investigation (Regulatory Post Marketing Commitment Plan)

> **NCT01470326** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 3187 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** Bazedoxifene

## Key facts

- **NCT ID:** NCT01470326
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 3187 (ACTUAL)
- **Last updated:** 2018-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01470326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01470326, "Viviant 20mg Special Investigation (Regulatory Post Marketing Commitment Plan)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01470326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*